{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T21:48:35Z","timestamp":1783806515449,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Jubilant Life Sciences"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.bmcl.2020.127763","type":"journal-article","created":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T20:37:40Z","timestamp":1608842260000},"page":"127763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Novel dual LSD1\/HDAC6 inhibitors for the treatment of multiple myeloma"],"prefix":"10.1016","volume":"34","author":[{"given":"M","family":"Naveen Sadhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanalakshmi","family":"Sivanandhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandru","family":"Gajendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramanyam","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purushottam","family":"Dewang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannan","family":"Murugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinatha","family":"Chickamunivenkatappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Zainuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreekala","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnakumar","family":"Vaithilingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridharan","family":"Rajagopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2020.127763_b0005","article-title":"Natural products as LSD1 inhibitors for cancer therapy","author":"Fang","year":"2020","journal-title":"Acta Pharm Sinica B"},{"issue":"11","key":"10.1016\/j.bmcl.2020.127763_b0010","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.4155\/fmc-2017-0068","article-title":"Advances toward LSD1 inhibitors for cancer therapy","volume":"9","author":"Fu","year":"2017","journal-title":"Future Med Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2020.127763_b0015","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0811-9","article-title":"LSD1\/KDM1A inhibitors in clinical trials: advances and prospects","volume":"12","author":"Fang","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.bmcl.2020.127763_b0020","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ccell.2018.02.002","article-title":"ORY-1001, a potent and selective covalent KDM1A inhibitor, for the treatment of acute leukemia","volume":"33","author":"Maes","year":"2018","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.bmcl.2020.127763_b0025","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.jtho.2019.06.021","article-title":"Phase I, open-label, dose-escalation study of the safety, pharmacokinetics, pharmacodynamics, and efficacy of GSK2879552 in relapsed\/refractory SCLC","volume":"14","author":"Bauer","year":"2019","journal-title":"J Thoracic Oncol"},{"issue":"1","key":"10.1016\/j.bmcl.2020.127763_b0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ccell.2015.06.002","article-title":"A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC","volume":"28","author":"Mohammad","year":"2015","journal-title":"Cancer Cell"},{"issue":"18","key":"10.1016\/j.bmcl.2020.127763_b0035","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1158\/0008-5472.CAN-08-4898","article-title":"Pomalidomide and Lenalidomide induce p21waf-1 expression in both Lymphoma and Multiple Myeloma through a LSD1-mediated epigenetic mechanism","volume":"69","author":"Escoubet-Lozach","year":"2009","journal-title":"Cancer Res"},{"issue":"21","key":"10.1016\/j.bmcl.2020.127763_b0040","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1182\/blood.V124.21.3410.3410","article-title":"LSD1 impairs the epithelial-mesenchymal transition (EMT) and osteoclastogenesis potency in multiple myeloma and synergistically induces cytotoxicity with HDAC inhibitors","volume":"124","author":"Gkotzamanidou","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bmcl.2020.127763_b0045","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1021\/acs.chemrev.7b00181","article-title":"Lysine acetylation goes global: from epigenetics to metabolism and therapeutics","volume":"118","author":"Ali","year":"2018","journal-title":"Chem Rev"},{"issue":"10","key":"10.1016\/j.bmcl.2020.127763_b0050","doi-asserted-by":"crossref","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.bmcl.2020.127763_b0055","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3390\/cancers12061664","article-title":"Roles of histone deacetylases and inhibitors in anticancer therapy","volume":"12","author":"Verza","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bmcl.2020.127763_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/7131802","article-title":"Efficacy of panobinostat for the treatment of multiple myeloma","volume":"2020","author":"Eleutherakis-Papaiakovou","year":"2020","journal-title":"J Oncol"},{"issue":"11","key":"10.1016\/j.bmcl.2020.127763_b0065","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S1470-2045(16)30375-8","article-title":"Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial","volume":"17","author":"Yee","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.bmcl.2020.127763_b0070","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1182\/blood-2011-10-387365","article-title":"Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma","volume":"119","author":"Santo","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bmcl.2020.127763_b0075","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-018-0654-9","article-title":"Histone deacetylase 6 in cancer","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bmcl.2020.127763_b0080","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.ejmech.2017.10.040","article-title":"Recent advances in the discovery of potent and selective HDAC6 inhibitors","volume":"143","author":"Wang","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"2","key":"10.1016\/j.bmcl.2020.127763_b0085","first-page":"499","article-title":"HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma","volume":"55","author":"Won","year":"2019","journal-title":"Int J Oncol"},{"issue":"3","key":"10.1016\/j.bmcl.2020.127763_b0090","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/leu.2017.322","article-title":"Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma","volume":"32","author":"Ray","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bmcl.2020.127763_b0095","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/carcin\/bgt033","article-title":"Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells","volume":"34","author":"Vasilatos","year":"2013","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.bmcl.2020.127763_b0100","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10549-011-1480-8","article-title":"Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells","volume":"131","author":"Huang","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.bmcl.2020.127763_b0105","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/neuonc\/nov041","article-title":"Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma","volume":"17","author":"Singh","year":"2015","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.bmcl.2020.127763_b0110","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/leu.2014.119","article-title":"Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells","volume":"28","author":"Fiskus","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bmcl.2020.127763_b0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41467-017-02242-4","article-title":"Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors","volume":"9","author":"Kalin","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2020.127763_b0120","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ejmech.2017.09.038","article-title":"Design and synthesis of tranylcypromine derivatives as novel LSD1\/HDACs dual inhibitors for cancer treatment","volume":"140","author":"Duan","year":"2017","journal-title":"Eur J Med Chem"},{"issue":"5","key":"10.1016\/j.bmcl.2020.127763_b0125","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk\u2010stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.bmcl.2020.127763_b0130","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-62885-0","article-title":"Concepts of double hit and triple hit disease in multiple myeloma, entity and prognostic significance","volume":"10","author":"Baysal","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmcl.2020.127763_b0135","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/456037","article-title":"Salvage therapy of multiple myeloma: the new generation drugs","volume":"2014","author":"Romano","year":"2014","journal-title":"Biomed Res Int"},{"issue":"27","key":"10.1016\/j.bmcl.2020.127763_b0140","doi-asserted-by":"crossref","first-page":"8058","DOI":"10.1021\/bi700664y","article-title":"Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine \u2020,\u2021","volume":"46","author":"Yang","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmcl.2020.127763_b0145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bbrc.2007.11.066","article-title":"Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 \u00c5","volume":"366","author":"Mimasu","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bmcl.2020.127763_b0150","doi-asserted-by":"crossref","first-page":"6827","DOI":"10.1021\/ja101557k","article-title":"Biochemical, structural and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2","volume":"132","author":"Binda","year":"2010","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2020.127763_b0155","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jpba.2016.03.036","article-title":"Determination of ulixertinib in mice plasma by LC-MS\/MS and its application to a pharmacokinetic study in mice","volume":"125","author":"Kumar","year":"2016","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"10.1016\/j.bmcl.2020.127763_b0160","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice","volume":"24","author":"Tomayko","year":"1989","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2030874X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2030874X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:38:34Z","timestamp":1760773114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X2030874X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":32,"alternative-id":["S0960894X2030874X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2020.127763","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel dual LSD1\/HDAC6 inhibitors for the treatment of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2020.127763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"127763"}}